Multidrug-resistant (MDR) enterococci are important nosocomial pathogens and a growing
clinical challenge. These organisms have developed resistance to virtually all antimicrobials …

Enterococci are Gram-positive bacteria that are found in plants, soil and as commensals of
the gastrointestinal tract of humans, mammals, and insects. Despite their commensal nature …

The discovery, commercialization, and routine administration of antimicrobial compounds to
treat infections revolutionized modern medicine and changed the therapeutic paradigm …

The genus Enterococcus consists of facultative gram-positive cocci that have been isolated
from a variety of animals, plants, and environmental sources. Although 58 species have …

Enterococcus faecalis, Enterococcus faecium and Staphylococcus aureus are both common
commensals and major opportunistic human pathogens. In recent decades, these bacteria …

Daptomycin (DAP) is a cyclic lipopeptide with in vitro activity against a variety of Gram‐
positive pathogens, including multidrug‐resistant organisms. Since its introduction into …

Lipopeptides are natural product antibiotics that consist of a peptide core with a lipid tail with
a diverse array of target organisms and mechanisms of action. Daptomycin (DAP) is an …

Daptomycin is a lipopeptide antimicrobial with in vitro bactericidal activity against Gram-
positive bacteria that was first approved for clinical use in 2004 in the United States. Since …

Daptomycin is a cyclic lipopeptide antibiotic, which was discovered in 1987 and entered the
market in 2003. To date, it serves as last resort antibiotic to treat complicated skin infections …

Treatment of multidrug-resistant enterococci has become a challenging clinical problem in
hospitals around the world due to the lack of reliable therapeutic options. Daptomycin (DAP) …